DOCSLIB.ORG

Why the Proportion of Transmission During Early-Stage HIV Infection Does Not Predict the Long-Term Impact of Treatment on HIV Incidence

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Why the Proportion of Transmission During Early-Stage HIV Infection Does Not Predict the Long-Term Impact of Treatment on HIV Incidence Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence Jeffrey W. Eaton1 and Timothy B. Hallett Department of Infectious Disease Epidemiology, Imperial College London, St Mary’s Hospital, London W2 1PG, United Kingdom Edited by Alan S. Perelson, Los Alamos National Laboratory, Los Alamos, NM, and accepted by the Editorial Board September 5, 2014 (received for review December 23, 2013) Antiretroviral therapy (ART) reduces the infectiousness of HIV- been infected recently affects the impact of treatment scale-up infected persons, but only after testing, linkage to care, and success- on HIV incidence. The model is calibrated to longitudinal HIV ful viral suppression. Thus, a large proportion of HIV transmission prevalence data from South Africa using a Bayesian framework. during a period of high infectiousness in the first few months after Thus, the model accounts for not only the early epidemic growth infection (“early transmission”) is perceived as a threat to the impact rate highlighted in previous research (5, 9, 18), but also the of HIV “treatment-as-prevention” strategies. We created a mathe- heterogeneity and sexual behavior change to explain the peak matical model of a heterosexual HIV epidemic to investigate how and decline in HIV incidence observed in sub-Saharan African the proportion of early transmission affects the impact of ART on HIV epidemics (32, 33). reducing HIV incidence. The model includes stages of HIV infection, The model calibration allows uncertainty about factors that flexible sexual mixing, and changes in risk behavior over the epi- determine the amount of early transmission, including the relative demic. The model was calibrated to HIV prevalence data from South infectiousness during early infection, heterogeneity in propensity Africa using a Bayesian framework. Immediately after ART was in- for sexual risk behavior, assortativity in sexual partner selection, troduced, more early transmission was associated with a smaller re- reduction in risk propensity over the life course, and population- duction in HIV incidence rate—consistent with the concern that wide reductions in risk behavior in response to the epidemic (32, 33). This results in multiple combinations of parameter values that a large amount of early transmission reduces the impact of treatment are consistent with the observed epidemic and variation in the on incidence. However, the proportion of early transmission was not amount of early transmission. We simulated the impact of a strongly related to the long-term reduction in incidence. This was treatment intervention and report how the proportion of early because more early transmission resulted in a shorter generation transmission correlates with the reduction in HIV incidence from time, in which case lower values for the basic reproductive number the intervention over the short- and long-term. (R0) are consistent with observed epidemic growth, and R0 was neg- atively correlated with long-term intervention impact. The fraction Results of early transmission depends on biological factors, behavioral pat- Model Calibration and Transmission During Epidemic Stage. The terns, and epidemic stage and alone does not predict long-term in- mathematical model was calibrated to the time series of HIV tervention impacts. However, early transmission may be an important prevalence among pregnant women in South Africa from 1990 determinant in the outcome of short-term trials and evaluation through 2008 (34) and HIV prevalence among adult men and of programs. womenaged15–49 y in three national household surveys in 2002, 2005, and 2008 (Fig. 1A). The HIV incidence rate grows rapidly HIV incidence | antiretroviral therapy | early infection | in the early 1990s, peaking in 1997 and declining by around HIV prevention intervention | mathematical model Significance ecent studies have confirmed that effective antiretroviral Rtherapy (ART) reduces the transmission of HIV among stable Antiretroviral treatment (ART), which prevents both morbidity – heterosexual couples (1 3). This finding has generated interest in and HIV transmission for persons infected with HIV, is now understanding the population-level impact of HIV treatment on thought to be central to strategies for controlling the spread of reducing the rate of new HIV infections in generalized epidemic HIV. One major concern has been that if a large proportion of settings (4). Research, including mathematical modeling (5–10), HIV transmission occurs early in infection, before persons can be implementation research (11), and major randomized controlled diagnosed and treated, the impact of treatment on reducing trials (12–14), are focused on how ART provision might be expanded new infections will be less. We use a mathematical model to strategically to maximize its public health benefits (15, 16). quantify how the proportion of early transmission will affect One concern is that if a large fraction of HIV transmission occurs the impact of intervention strategies, and explain underlying shortly after a person becomes infected, before the person can be epidemiological mechanisms for this. Model simulations sug- diagnosed and initiated on ART, this will limit the potential impact gest that—counter to expectations—the proportion of early of HIV treatment on reducing HIV incidence (9, 17, 18). Data transmission at the start of an ART intervention does not pre- suggest that persons are more infectious during a short period of dict the long-term intervention impact. “early infection” after becoming infected with HIV (19–22), al- though there is debate about the extent, duration, and determinants Author contributions: J.W.E. and T.B.H. designed research, performed research, contrib- of elevated infectiousness (18, 23). The amount of transmission that uted new reagents/analytic tools, analyzed data, and wrote the paper. occurs also will depend on patterns of sexual behavior and sexual This article is a PNAS Direct Submission. A.S.P. is a guest editor invited by the Editorial networks (17, 24–27). There have been estimates for the contri- Board. bution of early infection to transmission from mathematical models Freely available online through the PNAS open access option. (7, 17, 21, 24–26) and phylogenetic analyses (28–31), but these vary See Commentary on page 15867. widely, from 5% to above 50% (23). 1To whom correspondence should be addressed. Email: [email protected]. In this study, we use a mathematical model to quantify how the This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. proportion of transmission that comes from persons who have 1073/pnas.1323007111/-/DCSupplemental. 16202–16207 | PNAS | November 11, 2014 | vol. 111 | no. 45 www.pnas.org/cgi/doi/10.1073/pnas.1323007111 Downloaded by guest on October 1, 2021 37% (95% credible interval 30–43) over the next decade A B SEE COMMENTARY B 15 30% 2 (Fig. 1 ). The decline in incidence is the result of two factors: R = 0.56 infection saturation in the higher-risk groups and a reduction 25% in the unprotected sexual contact rate over time. It is esti- 10 20% mated that the contact rate declines by 28% (95% CI, 11–43; 15% parameter posterior distributions in Fig. S1). Density 5 The fraction of transmission occurring from individuals in each 10% Early transmission stage of infection evolves over the course of the epidemic (Fig. 0 5% 1C). During the early growth phase of the epidemic, most infected 10% 20% 30% 7x 10x 15x 30x 50x persons have been infected recently, and so most new infections Early transmission in 2010 Relative early infect. (log scale) result from highly infectious persons in early HIV infection (early Fig. 2. (A) Distribution in the percentage of transmission during early in- transmission). As the epidemic matures, the contribution of early fection in 2010. (B) Correlation between the relative infectiousness during transmission declines whereas the contribution of advanced stages early infection (on the log scale) and the proportion of early transmission. of infection grows. In the absence of ART scale-up, early transmission was estimated to account for 17% (95% CI, 12–24) of all transmission in 2010 (Fig. A Fig. 3 illustrates the correlation between the proportion of early 2 ). Much of the variation in early transmission was explained by transmission at the start of the intervention and the reduction in the relative infectiousness during early infection compared to R2 = B incidence over time. In the first year of the intervention, the re- chronic infection ( 56%; Fig. 2 ). Adjusting for the influence of duction in incidence was negatively correlated with the fraction of infectiousness during early infection, higher rates of moving from early transmission (Pearson’s r = −0.49) (Fig. 3A). This is con- higher- to lower-risk groups resulted in more early transmission sistent with the conventional wisdom that more early transmission because faster movement to low-risk groups results in more will result in less impact of treatment on reducing incidence. transmission occurring early after infection. These two parame- However, in the long term, the proportion of early transmission ters together explained 89% of the variation in early transmission A was not strongly predictive of the reduction in incidence, ex- in 2010 (Fig. S2 ). plaining only about 5% of the variation in intervention impact. In fact, after the 10th year, there was a modest positive correlation Early Transmission
Load more

Recommended publications
  • Vaccine to Prevent Human Papillomavirus
    Resolution No. 6/20-1 ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VACCINES FOR CHILDREN PROGRAM VACCINES TO PREVENT MENINGOCOCCAL DISEASE The purpose of this resolution is to update the resolution to reflect currently available meningococcal conjugate vaccines that can be used to prevent meningococcal disease attributable to serogroups A, C, W, and Y. VFC resolution 6/19-7 is repealed and replaced by the following: Meningococcal Conjugate Vaccines (MenACWY) Eligible Groups • Children aged 2 months through 10 years who are at increased risk for meningococcal disease attributable to serogroups A, C, W, and Y, including: o Children who have persistent complement component deficiencies (including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D) o Children taking a complement inhibitor (e.g., eculizumab [Soliris], ravulizumab [Ultomiris]) o Children who have anatomic or functional asplenia, including sickle cell disease o Children infected with human immunodeficiency virus (HIV) o Children traveling to or residing in countries in which meningococcal disease is hyperendemic or epidemic, particularly if contact with local population will be prolonged o Children identified to be at increased risk because of a meningococcal disease outbreak attributable to serogroups A, C, W, or Y • All children aged 11 through 18 years 1 Recommended Vaccination Schedule and Intervals The table below lists meningococcal conjugate vaccines currently available to prevent meningococcal disease attributable to serogroups A, C, W, and
    [Show full text]
  • An Atlas of Potentially Water-Related Diseases in South Africa
    AN ATLAS OF POTENTIALLY WATER-RELATED DISEASES IN SOUTH AFRICA Volume 2 Bibliography Report to the WATER RESEARCH COMMISSION by N Coetzee and D E Bourne Department of Community Health University of Cape Town Medical School WRC Report no. 584/2/96 ISBN 1 86845 245 X ISBN Set No 1 86845 246 8 1 CONTENTS VOLUME 2 BIBLIOGRAPHY 1 Introduction 2 2 Amoebiasis 3 3 Arthropod-borne viral diseases 7 4 Cholera 10 5 Diarrhoeal diseases in childhood 14 6 Viral hepatitis A and E 17 7 Leptospirosis 20 3 Pediculosis 22 9 Malaria 23 10 Poliomyelitis 29 11 Scabies 33 12 Schistosomiasis 35 13 Trachoma 39 14 Typhoid Fever 42 15 Intestinal helminthiasis 46 1. INTRODUCTION As many professionals involved in the management of water resources do not have a medical or public health background, it was thought that an explanatory bibliography of the major water related diseases in South Africa would be of use. Each section of the bibliography has (where appropriate) the following sections: 1. Aetiology 2. Transmission 3. Preventive and curative steps 4. South African data 5. References The MEDLINE data base of the national Library of Medicine, Washington DC, and the WATERLIT data base of the CSIR were searched. These were supplemented by South African journals and reports not appearing in the MEDLINE data base. 3 2. AMOEBIASIS 2.1. Aetiology The protozoan parasite Entamoeba histolytica which causes amoebiasis may exist as a hardy infective cyst or a more fragile and potentially pathogenic trophozoite (the "amoebic" form). Amoebiasis most commonly affects the colon and rectum as primary sitas of infection, with extraintestinal (most commonly liver abscesses), local or systemic, spread possible if not treated early.
    [Show full text]
  • Comparison of Annual and Biannual Mass Antibiotic Administration for Elimination of Infectious Trachoma
    ORIGINAL CONTRIBUTION Comparison of Annual and Biannual Mass Antibiotic Administration for Elimination of Infectious Trachoma Muluken Melese, MD, MPH Context Treatment recommendations assume that repeated mass antibiotic distri- Wondu Alemayehu, MD, MPH butions can control, but not eradicate or even locally eliminate, the ocular strains of Takele Lakew, MD, MPH chlamydia that cause trachoma. Elimination may be an important end point because of concern that infection will return to communities that have lost immunity to chla- Elizabeth Yi, MPH mydia after antibiotics are discontinued. Jenafir House, MPH, MSW Objective To determine whether biannual treatment can eliminate ocular chla- Jaya D. Chidambaram, MBBS mydial infection from preschool children and to compare results with the World Health Organization–recommended annual treatment. Zhaoxia Zhou, BA Design, Setting, and Participants A cluster-randomized clinical trial of biannual Vicky Cevallos, MT vs annual mass azithromycin administrations to all residents of 16 rural villages in the Kathryn Ray, MA Gurage Zone, Ethiopia, from March 2003 to April 2005. Kevin Cyrus Hong, BA Interventions At scheduled treatments, all individuals aged 1 year or older were Travis C. Porco, PhD, MPH offered a single dose of oral azithromycin either annually or biannually. Isabella Phan, MD Main Outcome Measure Village prevalence of ocular chlamydial infection and pres- ence of elimination at 24 months in preschool children determined by polymerase chain Ali Zaidi, MD reaction, correcting for baseline prevalence. Antibiotic treatments were performed af- Bruce D. Gaynor, MD ter sample collections. John P. Whitcher, MD, MPH Results Overall, 14 897 of 16 403 eligible individuals (90.8%) received their sched- uled treatment.
    [Show full text]
  • The Emergence of Epidemic Dengue Fever and Dengue Hemorrhagic
    Editorial The emergence of A global pandemic of dengue fever (DF) and dengue hemorrhagic fever (DHF) began in Southeast Asia during World War II and in the years following that con- epidemic dengue flict (1). In the last 25 years of the 20th century the pandemic intensified, with increased geographic spread of both the viruses and the principal mosquito vec- fever and dengue tor, Aedes aegypti. This led to larger and more frequent epidemics and to the emergence of DHF as tropical countries and regions became hyperendemic with hemorrhagic fever the co-circulation of multiple virus serotypes. With the exception of sporadic epidemics in the Caribbean islands, in the Americas: dengue and yellow fever were effectively controlled in the Americas from 1946 a case of failed until the late 1970s as a result of the Ae. aegypti eradication program conducted by the Pan American Health Organization (PAHO) (1, 2). This was a vertically struc- public health policy tured, paramilitary program that focused on mosquito larval control using source reduction and use of insecticides, primarily dichlorodiphenyltrichloroethane (DDT). This highly successful program, however, was disbanded in the early 1970s because there was no longer a perceived need and there were competing 1 Duane Gubler priorities for resources; control of dengue and yellow fever was thereafter merged with malaria control. Another major policy change at that time was the use of ultra-low-volume space sprays for killing adult mosquitoes (adulticides) as the rec- ommended method to control Ae. aegypti and thus prevent and control DF and DHF. Both of these decisions were major policy failures because they were inef- fective in preventing the re-emergence of epidemic DF and the emergence of DHF in the Region.
    [Show full text]
  • Meeting of the Board of Scientific Counselors, Office of Infectious Diseases
    MEETING OF THE BOARD OF SCIENTIFIC COUNSELORS, OFFICE OF INFECTIOUS DISEASES Centers for Disease Control and Prevention Tom Harkin Global Communications Center Atlanta, Georgia May 2–3, 2018 A one-and-a-half day, open public meeting of the Board of Scientific Counselors (BSC), Office of Infectious Diseases (OID), was held on May 2–3, 2018, at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. In addition to Board members and CDC staff, the meeting was attended by representatives of several public health partner organizations (appendix). The meeting included • Updates from OID, the Center for Global Health (CGH), and the National Centers for Immunization and Respiratory Diseases (NCIRD); HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP); and Emerging and Zoonotic Infectious Diseases (NCEZID) • Updates from the BSC Infectious Disease Laboratory Working Group (IDLWG) and the new OID– National Center for Environmental Health (NCEH)/Agency for Toxic Substances and Disease Registry (ATSDR) Vector-borne Diseases Workgroup • Updates on activities to address antimicrobial resistance by Veterinary Services (VS), Animal and Plant Health Inspection Service, U.S. Department of Agriculture (USDA/APHIS) and CDC • Presentations and discussion about CDC efforts to address the opioid epidemic, train the next generation of public health workers, and advance the CDC High Containment Laboratory Initiative The meeting also included a conversation with CDC Director Robert Redfield. Opening Remarks BSC Chair Ruth Lynfield, State Epidemiologist and Medical Director, Minnesota Department of Health, called the meeting to order and was joined in welcoming participants and facilitating introductions by Sonja Rasmussen, CDC Deputy Director for Infectious Diseases, and Sarah Wiley, the BSC/OID Designated Federal Official.
    [Show full text]
  • Waterborne Disease Risk Assessment Program 2019 Annual Report
    New York City Department of Health & Mental Hygiene Bureau of Communicable Disease & New York City Department of Environmental Protection Bureau of Water Supply Waterborne Disease Risk Assessment Program 2019 Annual Report March 2020 Prepared in accordance with Section 8.1 of the NYSDOH 2017 NYC Filtration Avoidance Determination i TABLE OF CONTENTS TABLE OF CONTENTS ................................................................................................................. i LIST OF TABLES ........................................................................................................................ iii LIST OF FIGURES ........................................................................................................................ iv LIST OF ACRONYMS ................................................................................................................... v ACKNOWLEDGMENTS .............................................................................................................. vi EXECUTIVE SUMMARY .......................................................................................................... vii 1. INTRODUCTION .................................................................................................................... 1 2. DISEASE SURVEILLANCE .................................................................................................. 1 2.1 Giardiasis .......................................................................................................................... 1
    [Show full text]
  • Recommended Adult Immunization Schedule
    Recommended Adult Immunization Schedule UNITED STATES for ages 19 years or older 2021 Recommended by the Advisory Committee on Immunization Practices How to use the adult immunization schedule (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Determine recommended Assess need for additional Review vaccine types, Control and Prevention (www.cdc.gov), American College of Physicians 1 vaccinations by age 2 recommended vaccinations 3 frequencies, and intervals (www.acponline.org), American Academy of Family Physicians (www.aafp. (Table 1) by medical condition and and considerations for org), American College of Obstetricians and Gynecologists (www.acog.org), other indications (Table 2) special situations (Notes) American College of Nurse-Midwives (www.midwife.org), and American Academy of Physician Assistants (www.aapa.org). Vaccines in the Adult Immunization Schedule* Report y Vaccines Abbreviations Trade names Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department Haemophilus influenzae type b vaccine Hib ActHIB® y Clinically significant postvaccination reactions to the Vaccine Adverse Event Hiberix® Reporting System at www.vaers.hhs.gov or 800-822-7967 PedvaxHIB® Hepatitis A vaccine HepA Havrix® Injury claims Vaqta® All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV) vaccines are covered by the Hepatitis A and hepatitis B vaccine HepA-HepB Twinrix® Vaccine Injury Compensation Program. Information on how to file a vaccine injury Hepatitis B vaccine HepB Engerix-B® claim is available at www.hrsa.gov/vaccinecompensation. Recombivax HB® Heplisav-B® Questions or comments Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Human papillomavirus vaccine HPV Gardasil 9® Spanish, 8 a.m.–8 p.m.
    [Show full text]
  • Immigration IZ– a Resource for Healthcare Providers
    Immigration IZ– A resource for healthcare providers Vaccines required for immigration applications should be age appropriate. 1 For example, if the applicant is 35 2 years of age, then he or she is required to receive tetanus and diphtheria toxoids vaccine (Td) or tetanus and 3 diphtheria toxoids and acellular pertus- sis vaccine (Tdap), MMR, and varicella 4 (if no history of varicella disease). If 5 the applicant had previously received a dose or doses of a required vaccine but 6 had not completed the series, then the next required dose should be adminis- 7 tered according to standard ACIP rec- ommendations. 8 Can still recommend other vaccinations 9 based on risk factors, but they are not required. 10 11 Please note that HPV and Zoster are not a requirement for immigration 12 1. A fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older. 2. Tdap for all pregnant women. Adults with incomplete vaccination will receive remaining doses. Adults with unknown history of vaccination will receive 3 doses (Tdap for first dose; remaning doses and boosters with Td) 3. A fourth dose of polio is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose. ministered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age 4. Documentation of provider-diagnosed disease is not considered acceptable evidence of immunity for measles, mumps, or rubella. Need at least one dose.
    [Show full text]
  • Sexually Transmitted Infections Treatment Guidelines, 2021
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized
    [Show full text]
  • Sexually Transmitted Diseases Treatment Guidelines, 2015
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Gonococcal Infections ...................................................................................... 60 Methods ....................................................................................................................1 Diseases Characterized by Vaginal Discharge .......................................... 69 Clinical Prevention Guidance ............................................................................2 Bacterial Vaginosis .......................................................................................... 69 Special Populations ..............................................................................................9 Trichomoniasis ................................................................................................. 72 Emerging Issues .................................................................................................. 17 Vulvovaginal Candidiasis ............................................................................. 75 Hepatitis C ......................................................................................................... 17 Pelvic Inflammatory
    [Show full text]
  • Scientific Collections and Emerging Infectious Diseases: Report of an Interdisciplinary Workshop
    Scientific Collections International Report (1) March 2015 Scientific Collections and Emerging Infectious Diseases: Report of an Interdisciplinary Workshop Phase 1: Detection OUTBREAK Phase 4: Prediction Phase 2: Characterization Phase 3: Mitigation Sc Scientific Collections International Scientific Collections International (SciColl) is a global consortium devoted to promoting the use and impact of object-based scientific collections across disciplines. SciColl’s member countries and institutions own and manage collections of objects used for research in archaeology, biology, biomedicine, earth and space sciences, technology, and other fields. SciColl’s mission is to increase the return on investment that countries and institutions make in their scientific collections by catalyzing international and interdisciplinary collaboration. Emerging Infectious Diseases, Food Security, Environmental Change, and Human Migration are the four research initiatives identified by SciColl for demonstrating the interdisciplinary value and impact of collections. SciColl is also developing an online Global Registry of Scientific Collections to increase access to information across disciplinary boundaries. This document presents a report of SciColl’s first activity in the area of Emerging Infectious Diseases. The workshop was designed by the Steering Committee: Diane diEuliis, Richard Jaffe, Manuela da Silva, Richard P. Lane, Tim Littlewood, Eileen Graham, and David E. Schindel, assisted by Adele Crane and Franco Ciammachilli. This report is a written record of the workshop presentations and discussions as compiled by the Steering Committee with input from the entire field of participants. A full list of workshop participants and their institutional affiliations can be found in the Appendix. Suggested Citation Scientific Collections International (2015 March). Scientific Collections and Emerging Infectious Diseases: Report of an Interdisciplinary Workshop.
    [Show full text]
  • CHAPTER 4 Infectious Disease
    CHAPTER 4 Infectious Disease 99 | Massachusetts State Health Assessment Infectious Disease This chapter provides information on preventing and controlling infectious diseases, and related trends, disparities, and resources in the Commonwealth of Massachusetts. It addresses the following infectious disease topic areas: • Foodborne Diseases • Healthcare-Associated Infections • Sexually Transmitted Infections • Human Immunodeficiency Virus • Viral Hepatitis • Tuberculosis • Vectorborne Diseases • Immunization • Selected Resources, Services, and Programs Chapter Data Highlights • Over 4,200 confirmed cases of foodborne disease in 2015 • HIV infections decreased by 31% from 2005 to 2014 • In 2015, hepatitis C case rates were 26 and 10 times higher, respectively, among White non-Hispanics compared to Asian non-Hispanics and Black non-Hispanics • In 2016, 190 cases of TB were reported in Massachusetts • Tickborne babesiosis increased 15% from 2015 to 2016 • Influenza and pneumonia ranked in the top ten leading causes of death among Massachusetts residents in 2014 100 | Massachusetts State Health Assessment Overview Infectious diseases have been causing human illness and death since the dawn of human existence. The effective prevention and control of these diseases is one of the major reasons for increases in life expectancy. In 1701, Massachusetts passed legislation requiring the isolation of the sick “for better preventing the spread of infection.”190 Since then, Massachusetts has led the nation in infection prevention and control. For example, Massachusetts was the only state to achieve a score of 10 out of 10 in Health Security Ranking which includes reducing healthcare-associated infections (HAIs), biosafety training in public health laboratories, public health funding commitment, national health security preparedness, public health accreditation, flu vaccination rates, climate change readiness,afety as well as a biosafety professional on staff and emergency health care access.
    [Show full text]